Skip to content
EntityQ7914945· pop 7· linked from 101 articles

vaniprevir

Sign in to save

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.

Wikidata facts

Mass
757.372049
Show 4 more facts
isomeric SMILES
CC[C@@H]1C[C@@]1(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C
canonical SMILES
CCC1CC1(C(=O)NS(=O)(=O)C2CC2)NC(=O)C3CC4CN3C(=O)C(NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C
chemical formula
C₃₈H₅₅N₅O₉S
Commons category
Vaniprevir
Sources (2)

via Wikidata · CC0

~1 min read

Article

1 sections
Contents
  • References

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.

==References==

Available in 6 languages

via Wikidata sitelinks · CC0

Connections

Categories